Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Hepatitis B Virus (HBV) Antibody (Anti-HBs) Booster Program for the Production of Hepatitis B Immune Globulin (HBIG)

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by:
Cangene Corporation
ClinicalTrials.gov Identifier:
NCT01311674
First received: February 25, 2011
Last updated: March 8, 2011
Last verified: March 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: December 2011
  Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)